Resources

59Resources found...

• Other

  Cepheid Receives World Health Organization Pre-Qualification of Xpert HIV-1 Viral Load Test

  

  On July 20, 2017, Cepheid received World Health Organization (WHO) prequalification for its Xpert® HIV-1 Viral Load (VL) test. The Xpert® HIV-1 VL test measures Human Immunodeficiency Virus type 1 (HIV-1) RNA in human plasma from individuals infected with HIV-1 in less than 90 minutes. Measurement of blood plasma HIV-1 RNA concentration (known as HIV viral load) using nucleic acid-based molecular diagnostic assays has been established as the standard of care in assessing HIV-positive patient prognosis and response to antiretroviral therapy. The Xpert® HIV-1 VL test is run on Cepheid’s GeneXpert System, the world’s most prevalent molecular diagnostics platform. By automating highly complex and time-consuming manual procedures, the GeneXpert allows institutions of any size to perform sophisticated genetic testing for organisms and genetic-based diseases.

   Author(s) Mr. Nqobile Ndlovu   Originally published on August 1, 2017   Posted on January 4, 2018

  ---

• Report

  ASLM in New York to support point-of-care device scale-up efforts in Africa

  

  Representatives from the African Society for Laboratory Medicine (ASLM), UNICEF and the Clinton Health Access Initiative, Inc. (CHAI) came together 17-18 August 2017 in New York City, United States, to review progress to date on the implementation of a joint point-of-care project and to refine coordination mechanisms to achieve greater impact.

   Author(s) Mr. Nqobile Ndlovu   Originally published on September 6, 2017   Posted on January 4, 2018

  ---

• Publication

  Pioneering New Diagnostics: Addressing Challenges and Implications for Point-of-Care Testing in African Settings

  

  Point-of-Care Testing: Why is it important?

  POCT2Imagine yourself in a city at the centre of one of the world’s deadliest disease outbreaks. You watch as your friends and relatives are struck down by an aggressive illness that kills roughly 50-90% of those affected. One evening, you go to bed tired and achy, awakening the next morning with fever and headache. You do the right thing and call the emergency number. You are told to head to the nearest healthcare facility, a holding centre far from your neighbourhood. You are greeted at the holding centre by security personnel wearing face masks, face shields and gloves. From a distance, they tell you to wash your hands in bleach solution and then point you through a metal door into the facility grounds. A nurse shows you to the “dry” waiting area on the far side of a bright orange plastic fence, an area reserved for suspect cases not yet exhibiting the “wet” symptoms of diarrhoea and vomiting. A few metres away, in another fenced area, you see a chaotic scene: sick people lying on the floor, outnumbered workers in protective suits diligently working to clean diarrhoea and vomit from around them. A nurse in a protective suit approaches you and asks about your symptoms from a distance. She takes your temperature using an infrared device and asks you to wait. Six hours go by and the surveillance team arrives to take a blood sample. Then you wait. Your symptoms worsen the following day. You wait for days at the holding centre. You share bathrooms, eating utensils, and living quarters with up to 100 other sick people. On the third day, your result comes back: you have tested negative for Ebola.

   Author(s) Laurel Oldach   Originally published on February 1, 2015   Posted on January 4, 2018

  ---

• Publication

  The performance of BD FACSPresto™ forCD4 T-cell count, CD4% and hemoglobin concentration test in Ethiopia

  Gebremicael, et al. report results from a technical evaluation of the BD FACSPresto Point-of-Care CD4 platform in Ethiopia using capillary and venous blood samples. Researchers found acceptable agreement with conventional systems for measuring CD4 count, CD4% and Hgb concentration. This paper was published in April 2017 by PLOS ONE.

   Author(s) GG, YB, BB, AG, DK, LV   Originally published on April 27, 2017   Posted on November 1, 2017

  ---

• Publication

  Impact of SMS/GPRS printers in reducing time to early infant diagnosis compared to 4 routine result reporting: a systematic review and meta-analysis

  Vojnov, et al., present results from a systematic review and meta-analysis to assess the benefit of using short message service (SMS) and general packet radio service (GPRS) printers to increase the efficiency of early infant diagnosis (EID) test result delivery compared with traditional courier, paper-based result delivery methods. The authors found that SMS/GPRS result delivery to facilities significantly reduced test turn-around time and should be considered for expedited delivery of EID and other centralized laboratory test results. This paper has been accepted by the Journal of Acquired Immune Deficiency Syndrome and was published online in August 2017.

   Author(s) TBD   Originally published on December 15, 2017   Posted on November 1, 2017

  ---

Filter by ticking the boxes below and then click apply

---